Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.
Company profile
Ticker
ATRS
Exchange
Website
CEO
Robert Apple
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ANTARES PHARMA INC, ANTARES PHARMA INC, ANTARES PHARMA INC /MN/, MEDI JECT CORP /MN/
SEC CIK
Corporate docs
IRS number
411350192
ATRS stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
3 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
Transcripts
ATRS
Earnings call transcript
2021 Q4
3 Mar 22
ATRS
Earnings call transcript
2021 Q3
4 Nov 21
ATRS
Earnings call transcript
2021 Q2
5 Aug 21
ATRS
Earnings call transcript
2021 Q1
6 May 21
ATRS
Earnings call transcript
2020 Q4
2 Mar 21
ATRS
Earnings call transcript
2020 Q3
5 Nov 20
ATRS
Earnings call transcript
2020 Q2
6 Aug 20
ATRS
Earnings call transcript
2020 Q1
5 May 20
ATRS
Earnings call transcript
2019 Q4
3 Mar 20
ATRS
Earnings call transcript
2019 Q3
5 Nov 19
Latest ownership filings
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 61.72 mm | 61.72 mm | 61.72 mm | 61.72 mm | 61.72 mm | 61.72 mm |
Cash burn (monthly) | 1.40 mm | (no burn) | 1.05 mm | (no burn) | 1.63 mm | (no burn) |
Cash used (since last report) | 34.46 mm | n/a | 25.76 mm | n/a | 40.06 mm | n/a |
Cash remaining | 27.26 mm | n/a | 35.96 mm | n/a | 21.65 mm | n/a |
Runway (months of cash) | 19.5 | n/a | 34.4 | n/a | 13.3 | n/a |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|